William Blair Believes Loxo Oncology (NASDAQ: LOXO) Still Has Room to Grow

By Jason Carr

William Blair analyst Raju Prasad maintained a Buy rating on Loxo Oncology (NASDAQ: LOXO) today. The company’s shares closed on Friday at $122.99, close to its 52-week high of $135.74.

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 33.0% and a 66.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Audentes Therapeutics, and PTC Therapeutics.

Currently, the analyst consensus on Loxo Oncology is Strong Buy and the average price target is $134.50, representing a 9.4% upside.

In a report issued on April 4, Oppenheimer also assigned a Buy rating to the stock with a $122 price target.

The company has a one-year high of $135.74 and a one-year low of $42.11. Currently, Loxo Oncology has an average volume of 399.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Loxo Oncology, Inc. is a biopharmaceutical company, which develops small molecule therapeutics for the treatment of cancer. Its pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. The company was founded by Joshua H.